Domperidone (Motilium, Prokinex) – conclusion of review of benefits and risks of harm
（Medsafe 2014.12.22）
http://www.medsafe.govt.nz/safety/EWS/2014/Domperidone.asp

EMAとほぼ同じ内容ですが、以下の医療専門職向けの注意喚起は注目です。

Relevant risk factors for cardiovascular events associated with domperidone include hypertension, hyperlipidaemia,obesity, diabetes, smoking and excessive alcohol consumption.

There is insufficient evidence to support the use of domperidone in childhood gastro-oesophageal reflux disease and it may not be suitable for chemotherapy- or radiotherapy-induced nausea and vomiting or post-operative nausea andvomiting.